AAPL   321.80 (+1.21%)
MSFT   182.90 (-0.19%)
FB   229.64 (+2.02%)
GOOGL   1,434.65 (+0.08%)
AMZN   2,470.82 (+1.16%)
NVDA   351.71 (-0.93%)
CGC   16.30 (-6.16%)
BABA   206.33 (-0.51%)
GE   6.69 (+1.67%)
AMD   53.62 (-0.33%)
T   31.10 (+0.75%)
ACB   14.17 (+0.64%)
F   5.86 (+2.63%)
GILD   75.26 (-3.30%)
DIS   118.86 (+1.33%)
BAC   24.63 (+2.11%)
BA   150.87 (+3.44%)
AAPL   321.80 (+1.21%)
MSFT   182.90 (-0.19%)
FB   229.64 (+2.02%)
GOOGL   1,434.65 (+0.08%)
AMZN   2,470.82 (+1.16%)
NVDA   351.71 (-0.93%)
CGC   16.30 (-6.16%)
BABA   206.33 (-0.51%)
GE   6.69 (+1.67%)
AMD   53.62 (-0.33%)
T   31.10 (+0.75%)
ACB   14.17 (+0.64%)
F   5.86 (+2.63%)
GILD   75.26 (-3.30%)
DIS   118.86 (+1.33%)
BAC   24.63 (+2.11%)
BA   150.87 (+3.44%)
AAPL   321.80 (+1.21%)
MSFT   182.90 (-0.19%)
FB   229.64 (+2.02%)
GOOGL   1,434.65 (+0.08%)
AMZN   2,470.82 (+1.16%)
NVDA   351.71 (-0.93%)
CGC   16.30 (-6.16%)
BABA   206.33 (-0.51%)
GE   6.69 (+1.67%)
AMD   53.62 (-0.33%)
T   31.10 (+0.75%)
ACB   14.17 (+0.64%)
F   5.86 (+2.63%)
GILD   75.26 (-3.30%)
DIS   118.86 (+1.33%)
BAC   24.63 (+2.11%)
BA   150.87 (+3.44%)
AAPL   321.80 (+1.21%)
MSFT   182.90 (-0.19%)
FB   229.64 (+2.02%)
GOOGL   1,434.65 (+0.08%)
AMZN   2,470.82 (+1.16%)
NVDA   351.71 (-0.93%)
CGC   16.30 (-6.16%)
BABA   206.33 (-0.51%)
GE   6.69 (+1.67%)
AMD   53.62 (-0.33%)
T   31.10 (+0.75%)
ACB   14.17 (+0.64%)
F   5.86 (+2.63%)
GILD   75.26 (-3.30%)
DIS   118.86 (+1.33%)
BAC   24.63 (+2.11%)
BA   150.87 (+3.44%)
Log in

NASDAQ:OASMOASMIA PHARMACE/ADR Stock Price, Forecast & News

$1.55
-0.38 (-19.69 %)
(As of 06/1/2020 01:06 PM ET)
Add
Compare
Today's Range
$1.55
Now: $1.55
$1.55
50-Day Range
$1.55
MA: $1.75
$2.28
52-Week Range
$0.94
Now: $1.55
$5.70
VolumeN/A
Average Volume24,780 shs
Market Capitalization$116.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company's approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops Doxophos, a formulation of XR17 and doxorubicin to treat cancer comprising leukaemia, breast cancer, and lymphoma; Docecal, a formulation of XR17 and docetaxel for the treatment of prostate, lung, and breast cancer; OAS-19, a cancer drug; and KB9520 to treat various types of cancer. The company also develops Doxophos Vet, a formulation to treat lymphoma in dogs. Oasmia Pharmaceutical AB (publ) was founded in 1990 and is based in Uppsala, Sweden.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OASM
CUSIPN/A
Phone461-850-5440

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$0.63 per share

Profitability

Net Income$-18,950,000.00
Net Margins-8,633.64%

Miscellaneous

Employees57
Market Cap$116.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OASM News and Ratings via Email

Sign-up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter.

OASMIA PHARMACE/ADR (NASDAQ:OASM) Frequently Asked Questions

How has OASMIA PHARMACE/ADR's stock been impacted by COVID-19 (Coronavirus)?

OASMIA PHARMACE/ADR's stock was trading at $1.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OASM shares have increased by 0.0% and is now trading at $1.55. View which stocks have been most impacted by Coronavirus.

Has OASMIA PHARMACE/ADR been receiving favorable news coverage?

Media stories about OASM stock have trended somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OASMIA PHARMACE/ADR earned a news impact score of 1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutOASMIA PHARMACE/ADR.

Who are some of OASMIA PHARMACE/ADR's key competitors?

What other stocks do shareholders of OASMIA PHARMACE/ADR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OASMIA PHARMACE/ADR investors own include G1 Therapeutics (GTHX), Protalix Biotherapeutics (PLX), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), Verastem (VSTM), Vaxart (VXRT) and Akari Therapeutics (AKTX).

Who are OASMIA PHARMACE/ADR's key executives?

OASMIA PHARMACE/ADR's management team includes the following people:
  • Mr. Mikael Asp, CEO & Head of Quality Assurance (Age 57)
  • Joakim Linden, Acting CFO
  • Ms. Och Annette Ljungmark, Head of Accounting and HR (Age 69)
  • Mr. John T. Cosby, Head of Regulatory Affairs (Age 57)
  • Mr. Dzianis Babrou, Head of Product Devel.

What is OASMIA PHARMACE/ADR's stock symbol?

OASMIA PHARMACE/ADR trades on the NASDAQ under the ticker symbol "OASM."

How do I buy shares of OASMIA PHARMACE/ADR?

Shares of OASM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OASMIA PHARMACE/ADR's stock price today?

One share of OASM stock can currently be purchased for approximately $1.55.

How big of a company is OASMIA PHARMACE/ADR?

OASMIA PHARMACE/ADR has a market capitalization of $116.20 million and generates $220,000.00 in revenue each year. OASMIA PHARMACE/ADR employs 57 workers across the globe.

What is OASMIA PHARMACE/ADR's official website?

The official website for OASMIA PHARMACE/ADR is www.oasmia.com.

How can I contact OASMIA PHARMACE/ADR?

OASMIA PHARMACE/ADR's mailing address is VALLONGATAN 1, UPPSALA V7, 75228. The company can be reached via phone at 461-850-5440 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.